Several other equities analysts have also issued reports on TYME. Zacks Investment Research upgraded Tyme Technologies from a hold rating to a buy rating and set a $3.50 price target on the stock in a research note on Friday, February 15th. BidaskClub upgraded Tyme Technologies from a sell rating to a hold rating in a research note on Wednesday, December 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock has an average rating of Hold and an average target price of $7.83.
Tyme Technologies stock traded down $0.20 during mid-day trading on Tuesday, reaching $2.06. 342,248 shares of the company were exchanged, compared to its average volume of 348,219. Tyme Technologies has a 12 month low of $1.93 and a 12 month high of $4.64. The firm has a market cap of $213.08 million, a PE ratio of -9.81 and a beta of 0.27.
Tyme Technologies (NASDAQ:TYME) last posted its quarterly earnings data on Monday, February 11th. The company reported ($0.08) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.08). On average, equities analysts expect that Tyme Technologies will post -0.29 earnings per share for the current year.
In other news, Director Douglas A. Michels acquired 20,000 shares of Tyme Technologies stock in a transaction that occurred on Thursday, February 14th. The shares were acquired at an average price of $3.26 per share, for a total transaction of $65,200.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 53.90% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its position in Tyme Technologies by 151.1% during the 4th quarter. BlackRock Inc. now owns 5,187,396 shares of the company’s stock worth $19,140,000 after acquiring an additional 3,121,655 shares during the last quarter. Vanguard Group Inc lifted its holdings in Tyme Technologies by 60.1% during the 3rd quarter. Vanguard Group Inc now owns 1,865,160 shares of the company’s stock worth $5,186,000 after buying an additional 699,871 shares during the period. Vanguard Group Inc. lifted its holdings in Tyme Technologies by 60.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,865,160 shares of the company’s stock worth $5,186,000 after buying an additional 699,871 shares during the period. Geode Capital Management LLC lifted its holdings in Tyme Technologies by 263.0% during the 4th quarter. Geode Capital Management LLC now owns 689,612 shares of the company’s stock worth $2,544,000 after buying an additional 499,627 shares during the period. Finally, Northern Trust Corp lifted its holdings in Tyme Technologies by 26.5% during the 4th quarter. Northern Trust Corp now owns 485,786 shares of the company’s stock worth $1,793,000 after buying an additional 101,734 shares during the period. Institutional investors and hedge funds own 16.14% of the company’s stock.
Tyme Technologies Company Profile
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.